This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

U.K.'s National Institute For Health And Clinical Evidence Accepts Alimera Sciences' ILUVIEN® Subgroup Data For Review

ATLANTA, Sept. 5, 2012 /PRNewswire/ -- Alimera Sciences, Inc., (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that the United Kingdom's National Institute for Health and Clinical Excellence (NICE) has accepted for consideration additional data in the form of an appendix to Alimera's comments on the preliminary Appraisal Consultation Document (ACD) previously issued by NICE for the ILUVIEN ® Single Technology Appraisal (STA).

NICE's Appraisal Committee, which issued the preliminary ACD in August, is currently evaluating the cost-effectiveness of ILUVIEN for the treatment of chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies.

On September 4, 2012, NICE informed Alimera that the Appraisal Committee required adequate time to thoroughly review the additional data. Therefore, the Second Appraisal Committee meeting, previously scheduled for September 11, 2012, has been rescheduled for October 11, 2012. According to NICE's Guide to the STA, new data is only accepted if it is likely to affect the provisional recommendations in the ACD.

As Alimera was drafting its response to the ACD, the company determined that ILUVIEN was more cost-effective in a pseudophakic patient subgroup of Alimera's FAME™ Study, providing additional support to its ACD response submission. As a result of diabetes, age or previous DME treatments, each patient in this subgroup had an artificial lens in his or her eye at the start of the study. Patients with an artificial lens cannot further develop a cataract in the treated eye due to their exposure to the corticosteroid delivered via ILUVIEN. These patients will not experience the transient reduction in visual acuity as the result of cataract development that occurred in some patients during the first two years of the FAME Study, nor will they incur the cost associated with cataract surgery.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,010.68 -115.44 -0.64%
S&P 500 2,107.39 -13.40 -0.63%
NASDAQ 5,070.0260 -27.95 -0.55%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs